Pulmatrix Inc. (PULM) and AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) Comparing side by side

Since Pulmatrix Inc. (NASDAQ:PULM) and AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pulmatrix Inc. N/A 0.00 20.50M -5.63 0.00
AmpliPhi Biosciences Corporation N/A 0.00 N/A -0.53 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Pulmatrix Inc. and AmpliPhi Biosciences Corporation.

Profitability

Table 2 provides us Pulmatrix Inc. and AmpliPhi Biosciences Corporation’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Pulmatrix Inc. 0.00% -168.5% -125.9%
AmpliPhi Biosciences Corporation 0.00% 0% 0%

Institutional and Insider Ownership

The shares of both Pulmatrix Inc. and AmpliPhi Biosciences Corporation are owned by institutional investors at 16.5% and 6.45% respectively. Pulmatrix Inc.’s share held by insiders are 6.2%. On the other hand, insiders held about 1.28% of AmpliPhi Biosciences Corporation’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Pulmatrix Inc. 4.76% 1.85% 35.77% -72.64% -75.82% -54.19%
AmpliPhi Biosciences Corporation -16.34% 9.17% 27.16% 7.43% -70.83% 54.1%

For the past year Pulmatrix Inc. has -54.19% weaker performance while AmpliPhi Biosciences Corporation has 54.1% stronger performance.

Summary

AmpliPhi Biosciences Corporation beats Pulmatrix Inc. on 5 of the 6 factors.

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. The companyÂ’s proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis (IPF). It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease. The company has an alliance with Celdara to develop an inhaled biologic to treat IPF. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. The company has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults. Its pipeline also includes AB-PA01 for the treatment of pseudomonas aeruginosa lung infections in cystic fibrosis and chronic rhinosinusitis patients. AmpliPhi Biosciences Corporation has a research collaboration agreement with Royal Brompton Hospital; a license agreement with University of Leicester to develop a phage therapy that targets and kills various clinically relevant toxin types of C. difficile; a cooperative research and development agreement with the U.S. Army Medical Research and Materiel Command and the Walter Reed Army Institute of Research to develop and commercialize bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and a clinical trial agreement with the University of Adelaide. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.